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Glomerular filtration rate (GFR) estimates from serum
creatinine has not been generalizable across all populations.
Cystatin C has been proposed as an alternative marker for
estimating GFR. The objective of this study was to compare
cystatin C with serum creatinine for estimating GFR among
different clinical presentations. Cystatin C and serum
creatinine levels were obtained from adult patients (n¼ 460)
during an evaluation that included a GFR measurement by
iothalamate clearance. Medical records were abstracted for
clinical presentation (healthy, native chronic kidney disease
or transplant recipient) at the time of GFR measurement. GFR
was modeled using the following variables: cystatin C (or
serum creatinine), age, gender, and clinical presentation. The
relationship between cystatin C and GFR differed across
clinical presentations. At the same cystatin C level, GFR was
19% higher in transplant recipients than in patients with
native kidney disease (Po0.001). The association between
cystatin C and GFR was stronger among native kidney
disease patients than in healthy persons (Po0.001 for
statistical interaction). Thus, a cystatin C equation was
derived using only patients with native kidney disease
(n¼ 204). The correlation with GFR (r2¼ 0.853) was slightly
higher than a serum creatinine equation using the same
sample (r2¼ 0.827), the Modification of Diet in Renal Disease
equation (r2¼ 0.825) or the Cockcroft–Gault equation
(r2¼ 0.796). Averaged estimates between cystatin C and
serum creatinine equations further improved correlation
(r2¼ 0.891). Cystatin C should not be interpreted as purely
a marker of GFR. Other factors, possibly inflammation or
immunosuppression therapy, affect cystatin C levels. While
recognizing this limitation, cystatin C may improve GFR
estimates in chronic kidney disease patients.
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Ideally, glomerular filtration rate (GFR) should be deter-
mined with a method that is convenient, inexpensive, and
accurate. GFR can be estimated from serum creatinine using
the Modification of Diet in Renal Disease (MDRD) or
Cockcroft–Gault equations.1,2 However, these equations have
not been generalizable across all clinical presentations. For
example, the MDRD equation, derived with chronic kidney
disease (CKD) patients, underestimated GFR in healthy
persons by 29%.3 This occurred in part because the strength
of association between serum creatinine and GFR is much
less among healthy persons compared to that of patients with
CKD.3–5 The MDRD equation also overestimates the strength
of association between GFR and serum creatinine in type I
diabetes pateints with normal serum creatinine levels.6
Studies have suggested that serum cystatin C may have
advantages over serum creatinine for estimating GFR.
Cystatin C is a low molecular weight basic protein (13 kDa)
that is freely filtered and metabolized after tubular re-
absorption.7,8 Studies have reported that cystatin C is less
influenced by age, gender and muscle mass than serum
creatinine.9–11 However, in at least one general population
study, cystatin C was found to be influenced by several factors
including age, gender, body size, cigarette smoking and
C-reactive protein independent of creatinine clearance.12
Another study suggested that cystatin C was not simply a
marker of GFR because it predicted future cardiovascular
events independent of estimated creatinine clearance.13
A potential problem with these studies was the evaluation
of cystatin C with serum creatinine-based equations or
creatinine clearance instead of with measured GFR.
The primary objective of this study was to assess the
relationship between cystatin C and GFR (iothalamate
clearance) among clinical presentations that commonly lead
to a GFR measurement. The secondary objective was to
compare a cystatin C equation to a serum creatinine equation
for estimating GFR.
RESULTS
Table 1 presents demographic characteristics and laboratory
measurements, overall and by clinical presentation. GFR
estimated by the abbreviated MDRD equation or the
Cockcroft–Gault equation was similar to GFR measured by
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iothalamate clearance except in the healthy group. Transplant
recipients were classified by kidney graft alone (n¼ 103,
50%), liver graft (n¼ 55, 27%), heart graft (n¼ 30, 15%),
pancreas graft (n¼ 15, 7%), and lung graft (n¼ 3, 1%).
Patients with non-kidney grafts could be further classified as
those who had an iothalamate clearance as part of routine
follow-up versus those who had it for CKD, but this
distinction was not important in multivariable models.
The relationship between cystatin C and measured GFR
(Figure 1a), and between serum creatinine and measured
GFR (Figure 1b) is shown on a logarithmic scale.
Natural logarithmic (ln) GFR was regressed on ln analyte
for each clinical presentation. There was a stronger regres-
sion fit between ln GFR and ln cystatin C than between
ln GFR and ln serum creatinine for the native kidney
disease group (r2¼ 0.853 versus 0.770), the transplant
recipient group (r2¼ 0.768 versus 0.671), and the healthy
group (r2¼ 0.382 versus 0.123). There was an upward
shift in the regression line between GFR and cystatin C
among transplant recipients compared to those with native
kidney disease (Figure 1a); this was not observed between
GFR and serum creatinine (Figure 1b). The healthy group
had a more gradual slope than the native kidney disease
group when GFR was regressed on either cystatin C or serum
creatinine.
Table 2 presents the effect of predictor variables on GFR in
a multivariable model based on cystatin C versus a similar
model based on serum creatinine. Both a 50% increase in
cystatin C and a 50% increase in serum creatinine were
associated with a 39% decrease in GFR. Age was a stronger
predictor of GFR in a model based on serum creatinine than
in a model based on cystatin C (Po0.002 for both). At the
same serum creatinine level, female subjects had a 23% lower
GFR than male subjects (Po0.001), but there was no
difference at the same cystatin C level (P¼ 0.18). At the
same serum creatinine level, healthy persons had a 15%
higher GFR than patients with native kidney disease
(P¼ 0.002), but there was no difference at the same cystatin
C level (P¼ 0.28). At the same cystatin C level, transplant
recipients (kidney, liver, heart, pancreas, or lung) had a 19%
higher GFR (Po0.001) than patients with native kidney
Table 1 | Descriptive characteristics and laboratory measurements, overall and by clinical presentation
Overall
Healthy
(potential donors)
Native
kidney disease
Kidney
transplant recipient
Other
transplant recipient
Sample size 460 50 204 103 103
Female, n (%) 193 (42) 34 (68) 92 (45) 38 (37) 29 (28)
Caucasian, n (%) 446 (97) 50 (100) 197 (97) 100 (97) 99 (96)
Diabetic, n (%) 74 (16) 0 (0) 37 (18) 19 (18) 18 (17)
Age (years) 51715 41711 55716 49713 51712
Height (cm) 171710 16879 171710 171710 171710
Weight (kg) 84720 80717 86723 83720 84717
Body mass index (kg/m2) 2976 2876 2977 2875 2876
Iothalamate GFR (ml/min/1.73 m2) 57729 101716 51729 52718 54722
MDRD GFRa (ml/min/1.73m2) 55724 86713 50725 51715 57721
C-G GFRb (ml/min/1.73 m2) 55725 87719 49726 50715 55719
Serum creatinine (mg/dl) 1.670.9 0.970.2 1.871.2 1.570.4 1.570.6
Cystatin C (mg/l)b 1.570.8 0.870.2 1.670.9 1.670.6 1.670.7
aMDRD GFR=186 SCr1.154 age0.203 (0.742 if female) (1.21 if black).1,14
bC-G GFR=((140-age) weight(kg)/(SCr 72)) (0.85 if female) (1.73/body surface area) 0.84.2,14
Entries are mean7s.d. or count (percent) where appropriate.
10
6
5
4
100
60
50
40
30
20
G
FR
 (m
l/m
in 
pe
r 1
.73
 m
2 )
10
6
5
4
100
60
50
40
30
20
G
FR
 (m
l/m
in 
pe
r 1
.73
 m
2 )
210.90.80.70.60.5 3 4 5 6 7 8
210.90.80.70.60.5 3 4 5 6 7 8
Cystatin C (mg/l)
Healthy persons
Native kidney disease
Transplant recipients
Healthy persons
Native kidney disease
Transplant recipients
Serum creatinine (mg/dl) 
a
b
Figure 1 | Relationship between (a) cystatin C or (b) serum
creatinine and measured GFR (iothalamate clearance) in 460
patients on a logarithmic scale. The closed circles represent healthy
persons (n¼ 50). The open circles represent patients with native
kidney disease only (n¼ 204). The crosses represent patients with
solid organ transplants (n¼ 206). The regression lines for all three
patient groups (native kidney disease, transplant recipients, and
healthy) are shown. For (a) cystatin C, the regression lines represent
GFR prediction equations for patients with native kidney disease
(equation (1)) and transplant recipients (equation (3)).
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disease. At the same serum creatinine level, liver transplant
recipients had a 10% lower GFR (P¼ 0.007) than patients
with native kidney disease, but there was no difference with
non-liver transplant recipients (P¼ 0.36).
As seen graphically by the different slopes in Figure 1,
there was a statistical interaction between serum analyte
and healthy versus native kidney disease status in the
prediction of GFR (Po0.001 for both cystatin C and serum
creatinine). To understand the potential importance of these
statistical interactions, ln GFR was modeled separately in the
healthy group and the native kidney disease group (Table 3).
In the healthy group, a difference in cystatin C or serum
creatinine was less strongly associated with a difference
in GFR compared to that in the native kidney disease
group. Furthermore, in the healthy group compared to the
native kidney disease group, age and gender were stronger
predictors of GFR in a cystatin C model, but weaker
predictors of GFR in a serum creatinine model. For both
cystatin C and serum creatinine models, the root mean
square error was approximately half for the healthy group
compared to the native kidney disease group. Although
subtle, there was also a statistical interaction between cystatin
C and transplant recipient versus native kidney disease
status in the prediction of GFR (P¼ 0.02). A 50% increase in
cystatin C was associated with a 37.1% decrease in GFR for
the transplant recipient group compared to a 40.3% decrease
in GFR for the native kidney disease group.
As shown in Figure 1a and Tables 2 and 3, the relationship
between cystatin C and GFR varied across clinical presenta-
tion. Thus, we developed cystatin C and serum creatinine
equations using only the native kidney disease group
(equations (1) and (2), n¼ 204). For the cystatin C model,
gender was not statistically significant (P¼ 0.71) and age
was only borderline significant (P¼ 0.06). Including these
variables only increased the r2 by 0.003. Thus, the final
cystatin C equation did not include age or gender. A separate
cystatin C equation was also developed for transplant
recipients (equation (3), n¼ 206). For convenience, Table 4
provides the corresponding cystatin C levels for each stage
of CKD.1
Table 2 | Effect of predictor variables on GFR in a model based on cystatin C versus a similar model based on serum creatinine
(sample size=460)
% Difference in measured GFR (95% confidence interval)
Cystatin C model Serum creatinine model
Cystatin C (per 50% increase) 38.8 (40.2 to 37.3) —
Serum creatinine (per 50% increase) — 39.0 (40.5 to 37.6)
Age (per 50% increase) 4.8 (7.5 to 1.9) 8.2 (11.0 to 5.3)
Male (n=267) Ref Ref
Female (n=193) 3.1 (7.3 to 1.4) 23.2 (26.9 to 19.3)
Native kidney disease (n=204) Ref Ref
Healthy (n=50) 4.7 (3.6 to 13.7) 14.8 (5.5 to 24.9)
Kidney recipient (n=103) 18.3 (11.8 to 13.7) 2.5 (3.5 to 9.0)
Liver recipient (n=55) 19.1 (11.0 to 27.8) 9.9 (16.3 to 2.9)
Heart recipient (n=30) 25.5 (14.4 to 37.6) 3.8 (5.9 to 14.5)
Other organ recipienta (n=18) 13.7 (1.4 to 27.3) 2.9 (14.0 to 9.6)
Model fit (r2)b 0.852 0.832
Root mean square error (%)c 26.5 28.4
aPancreas or lung.
bModel fit or coefficient of determination (r2) is the proportion of between patient variability in measured GFR explained by the model.
cRoot mean square error is an average error between measured GFR and estimated GFR given as a percentage.
Table 3 | Effect of predictor variables on GFR in cystatin C models compared to serum creatinine models by clinical
presentation (native kidney disease, n=204; healthy, n=50)
% Difference in measured GFR (95% confidence interval)
Cystatin C Models Serum creatinine models
Clinical presentation Native kidney disease Healthy Native kidney disease Healthy
Cystatin C (per 50% increase) 40.3 (42.1 to 38.4) 20.2 (26.0 to 14.0) — —
Serum creatinine (per 50% increase) — — 39.0 (41.0 to 36.9) 18.4 (29.3 to 5.8)
Age (per 50% increase) 4.3 (8.5 to 0.2) 8.0 (12.8 to 3.1) 11.4 (15.6 to 7.0) 6.6 (12.5 to 0.3)
Male Ref Ref Ref Ref
Female 1.4 (5.7 to 9.1) 4.9 (12.0 to 2.8) 26.2 (32.1 to 19.7) 10.9 (21.8 to 1.6)
Model fit (r2)a 0.856 0.493 0.827 0.237
Root mean square error (%)b 29.0 13.1 32.8 16.3
aModel fit or coefficient of determination (r2) is the proportion of between patient variability in measured GFR explained by the model.
bRoot mean square error is an average error between measured GFR and estimated GFR given as a percentage.
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Native CKD
GFR ¼ 66:8ðcystatin CÞ1:30 ð1Þ
Native CKD
GFR ¼ 273ðserum creatinineÞ1:22
age0:2990:738 ðif femaleÞ ð2Þ
Transplant recipient
GFR ¼ 76:6ðcystatin CÞ1:16 ð3Þ
The correlation of the cystatin C equation (equation (1),
r2¼ 0.853) was higher than the serum creatinine equation
derived using the same sample (equation (2), r2¼ 0.827),
although this did not reach statistical significance
(P¼ 0.15).15 It was also higher than the MDRD equation
(r2¼ 0.825) and the Cockcroft–Gault equation (r2¼ 0.796).
The cystatin C equation also appeared to perform slightly
better than a serum creatinine equation when applied
to independent datasets approximated with bootstrapping.
The r2 adjusted for optimism was 0.852 for the cystatin C
equation (equation (1)) and was 0.821 for the serum creati-
nine equation (equation (2)). The cystatin C equation
derived with transplant recipients (equation (3)) had an r2
of 0.768 and an r2 adjusted for optimism of 0.766.
A composite equation for the native kidney disease group
based on cystatin C, serum creatinine, age, and gender had the
best model fit (r2¼ 0.892, equation not shown). This was signifi-
cantly higher than the serum creatinine equation (Po0.0001).15
However, a similar model fit (r2¼ 0.891) was obtained regres-
sing measured GFR on the mean of the cystatin C equation
(equation (1)) and the serum creatinine equation (equation (2)).
In other words, when both cystatin C and serum creatinine are
available, averaging the GFR estimates by each analyte improved
correlation with measured GFR. As equation models predicted
logarithmic GFR, the geometric mean was used:
Composite estimated GFR ðeGFRÞ
¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
ðcystatin C eGFRÞðserum creatinine eGFRÞ
p ð4Þ
DISCUSSION
This study characterized the relationship between cystatin C
and measured GFR (iothalamate clearance) in a variety of
clinical presentations. At the same cystatin C level, transplant
recipients had a 19% higher GFR than native kidney disease
patients. As expected, there was a much stronger association
between cystatin C and GFR among native kidney disease
patients (r2¼ 0.853) than among healthy persons (r2¼ 0.382).
Because clinical presentation was an important predictor of
GFR, a cystatin C equation was derived with native kidney
disease patients only. Averaging the estimated GFR between
a cystatin C equation and a serum creatinine equation
improved the prediction of GFR over a serum creatinine
equation alone in CKD patients.
These findings help clarify the relationship between
cystatin C and GFR as compared to serum creatinine and
GFR. The relationship between either serum analyte with
GFR differed among clinical presentations. This, in part, may
explain the discrepancy among prior studies that compared
cystatin C with serum creatinine.16 For this study, equations
were only developed for patients with a clinical diagnosis of
CKD. A diagnosis of CKD was based on an elevated serum
creatinine level, other evidence of kidney damage (e.g.,
proteinuria) or a clinical presentation where most patients
have reduction in GFR (transplant recipient). GFR can be
estimated with a cystatin C equation for native kidney disease
patients (equation (1)) or with a cystatin C equation for
transplant recipients (equation (3)) as well as with the
MDRD equation. Improved prediction may be obtained by
averaging (geometric mean) the estimated GFR from the
appropriate cystatin C equation with the MDRD equation.
When clinical presentation narrows the GFR distribution,
this will decrease modeling error in the GFR estimate. This
was demonstrated by the lower root mean square error for the
healthy group compared to that for the native kidney disease
groups (Table 3). Thus, it is important to have a diagnosis of
CKD before applying these equations to estimate GFR.
Any GFR estimated by a serum analyte should still be
interpreted with caution. Confounding factors associated
with cystatin C (possibly inflammation or immunosuppres-
sion therapy) or serum creatinine (muscle mass or protein
intake) may lead to inaccurate GFR estimates. This inherent
limitation from factors that influence serum analyte levels
independent of GFR is illustrated in Figure 2. With
prediction equations, several analyte factors (production,
tubular secretion, tubular reabsorption, and extra-renal clear-
ance) are not directly measured. Instead they are assumed to
Table 4 | Cystatin C levels for determining stage of CKD
Cystatin C level
Stagea Description GFR rangea (ml/min/1.73 m2) Native kidney diseaseb Transplant recipientc
1 Normal or increased GFR X90 p0.80 p0.87
2 Mildly decreased GFR 60 to 89 0.80 to 1.09 0.87 to 1.23
3 Moderately decreased GFR 30 to 59 1.10 to 1.86 1.24 to 2.24
4 Severely decreased GFR 15 to 29 1.87 to 3.17 2.25 to 4.10
5 Kidney Failure o15 43.17 44.10
aGFR estimates and CKD stage will be inaccurate if there is a calibration difference with the Dade-Behring BN II Nephelometer assay used in this study.
bUsing the prediction equation: GFR=66.8 (cystatin C)1.30.
cUsing the prediction equation: GFR=76.6 (cystatin C)1.16.
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be constant or are modeled based on easily measured
characteristics (e.g. age and gender) of the population used
to derive the equation. Thus, an equation will not be accurate
if the modeled effect of these analyte factors based on the
equation population is incorrect for a particular patient
(Figure 2).
For example, applying an equation derived in native
kidney disease patients to a liver graft recipient will
overestimate GFR by serum creatinine but underestimate
GFR by cystatin C (Table 2). For serum creatinine, liver
disease among liver graft recipients will decrease creatinine
production leading to an overestimation of GFR.17 For
cystatin C, the inflammation or immunosuppression therapy
associated with having a liver graft may increase cystatin C
production leading to an underestimation of GFR.
The methods used in this study were chosen to minimize
bias in the comparison of two different serum analytes.
Sampling or measurement bias can occur when applying
previously derived statistical models (e.g., MDRD equation
and Cockcroft–Gault equation) to new data. Thus, compar-
isons were made between statistical models specifically
derived for this study that varied either the serum analyte
or the sampled population. This improved internal validity
for the comparison between cystatin C and serum creatinine
(as measured in this study) for predicting GFR (as measured
in this study) among different populations (as sampled in
this study). Finally, samples were not identified by measured
GFR, because measured GFR was the dependent variable in
the regression models.
The results of this study are consistent with previously
published studies. The 19% higher GFR at the same cystatin
C level among transplant recipients compared to native
kidney disease patients is consistent with reports by other
investigators.18,19 The mechanism for this finding is not
understood, but plausible hypotheses include increased
cystatin C production from systemic inflammation12,13,20 or
use of immunosuppresion therapy21,22 among transplant
recipients. In this study, the regression fit between ln GFR
and ln cystatin C was stronger than between ln GFR and
ln serum creatinine for each clinical presentation. This was
consistent with a meta-analysis that found cystatin C to be
either superior or equivalent to serum creatinine in the
correlation with GFR.16 Another study also found that a
cystatin C (Dade–Behring assay) equation (r2¼ 0.91) had a
better model fit than a serum creatinine equation (r2¼ 0.84),
but effects of clinical presentation, body size, age, and sex
were not considered in the comparison. The equation for that
study, GFR (ml/min)¼ 77.2 cystatin C1.26, gives GFR
estimates 15–20% higher than the native kidney disease
equation (equation (1)) of this study.23
There were several potential limitations to this study. First,
patients were classified into clinical presentations based on a
medical chart review. To decrease misclassification bias,
patients were only grouped by levels of easily identifiable
clinical characteristics. Second, among native kidney disease
patients, only those with an increased severity of illness, such
that a nephrologist would measure the patient’s GFR, were
represented. Thus, patients with microalbuminuria and a
normal serum creatinine level were inadequately represented
in the native kidney disease group. Third, the generalizability
of the cystatin C equation needs to be tested in other centers
with more diverse racial groups and different mixtures of
CKD etiologies. Finally, any calibration differences between
the Dade-Behring BN II Nephelometer used in this study and
other cystatin C assays can lead to inaccurate GFR estimates,
a well-described problem with serum creatinine equations.24
In conclusion, the relationship between cystatin C and
GFR can depend on the clinical presentation. In patients with
CKD, a cystatin C equation is complementary to the MDRD
equation or other serum creatinine equations for improving
GFR estimates. Depending on the clinical setting, estimated
GFR with a cystatin C equation can be averaged with a serum
creatinine equation or used in place of the serum creatinine
equation. For example, among patients with very high or very
low muscle mass, a cystatin C equation alone may be
preferential. A better understanding of the factors that effect
cystatin C levels independent of GFR could potentially
improve Cystatin C equations and determine the best settings
for their application.
MATERIALS AND METHODS
Study subjects
A previously reported series of consecutive patients (n¼ 502) had an
outpatient GFR measurement by iothalamate clearance, between 27
October 1999 and 3 March 2000 and agreed to participate in the
study.3 Medical records were abstracted for demographic and
clinical characteristics present at the time of the iothalamate
clearance. Clinical presentation was grouped into three mutually
exclusive categories: native CKD, solid-organ transplant recipient
(with or without known CKD), and healthy (potential kidney
donor). Among the native kidney disease patients, the suspected
etiology was hypertension or unknown (36%), diabetes mellitus
(13%), other glomerulopathy (26%), and other non-glomerulo-
pathy (25%).
Transplant recipients were further divided into those with a
kidney graft alone and those with other organ grafts (liver, heart,
pancreas, or lung) with or without a kidney graft. Transplant
recipients typically have GFR measurements during routine
Serum analyte
level (Measured)
Glomerular filtration
rate
Other analyte factors
(Not measured) 
Production rate 
Secretion rate 
Re-absorption rate 
Extra-renal clearance rate
Equation population
The patient
Figure 2 | Diagram that demonstrates an inherent problem with
GFR prediction equations. An equation may not be accurate if
unmeasured analyte factors (production, secretion, reabsorption, and
extra-renal clearance) are modeled incorrectly for a particular patient
(or patient group).
Kidney International (2006) 69, 399–405 403
AD Rule et al.: GFR estimated by cystatin C o r i g i n a l a r t i c l e
outpatient follow-up when serum creatinine levels are stable.
Patients who did not fit into the above categories were excluded
due to inadequate sample size and heterogeneity (n¼ 32). This
included protocol evaluation for potential non-kidney transplant
recipients (pancreas, n¼ 5; heart, n¼ 6; or lung, n¼ 9), spinal cord
injury patients with neurogenic bladders being screened for kidney
disease (n¼ 8), a cancer patient who needed chemotherapy dosing
(n¼ 1), and reason for GFR measurement indeterminate (n¼ 3).
Children (ages o17 years) were also excluded (n¼ 10).
Laboratory measurements
All patients had a non-radiolabeled iothalamate clearance using a
previously described standard laboratory method.25 Briefly, after
oral hydration with 4–6 glasses of water, patients received a
subcutaneous injection of non-radiolabeled iothalamate (Conray,
Mallinckrodt Medical, St Louis, MO, USA). Following a 1-h
equilibrium period, the patient voided, the first serum sample was
drawn and a timed urine collection was begun. A sonographic
scanner assessed bladder emptying and a bladder catheter was placed
in patients with urinary retention. Following the timed urine
collection (approximately 45–60 min), a second serum sample was
obtained. GFR was calculated by the clearance equation (UIoV/PIo
where UIo and PIo are the urine and plasma concentrations of
iothalamate, and V is the urine flow) using the mean of two serum
samples and one urine sample assayed for iothalamate via capillary
electrophoresis. The between-day assay coefficient of variation was
4.3%. All GFR measurements were standardized for body surface
area (per 1.73 m2) by multiplying by 1.73 and dividing by body
surface area.26,27
Cystatin C and creatinine levels were assayed from the first serum
sample obtained during the iothalamate clearance test. Cystatin C
was assayed by particle-enhanced immuno-nephelometry (Dade-
Behring BN II Nephelometer). The between-day assay coefficient of
variation was 3.5%. The assay showed linearity based on serial
dilutions (measured¼ 0.996 expectedþ 0.015; n¼ 16) over a
range of 0.16 to 2.61 mg/l. Samples showed stability at room
temperature (up to 7 days), when frozen at 201C (up to 2 years)
and through three freeze–thaw cycles. Serum creatinine was
measured by the uncompensated rate-Jaffe reaction (Hitachi 911
auto-analyzer). The between-day assay coefficient of variation was
4.7% at 1.1 mg/dl and 1.8% at 5.6 mg/dl. GFR was estimated using
the abbreviated MDRD equation14,28 and the Cockcroft–Gault
equation (standardized for body surface area and adjusted to
predict GFR in the same native kidney disease population used to
derive the MDRD equation).2,14 The original Cockcroft–Gault
equation predicts creatinine clearance and because of tubular
creatinine secretion, it overestimates GFR in CKD patients.
Statistical analysis
Univariate statistics (frequency, mean, standard deviation) were
assessed overall and stratified by clinical presentation. For each
clinical presentation group, ln GFR was regressed on ln analyte
(cystatin C or serum creatinine). GFR was ln transformed for
constant variability. Cystatin C and serum creatinine levels were ln
transformed for linearity within groups. Multiple linear regression
was used to predict ln GFR with the covariates: ln analyte, ln age,
female (0–1 indicator variable) and clinical presentation (0–1
indicator variables with native kidney disease as the reference
group). Age was ln transformed to allow easier comparison with the
MDRD equation, but findings were similar when age was not ln
transformed. Height and weight were not included as predictors in
models, because GFR had been standardized for body surface area
using a formula based on height and weight.27 Interaction terms
between the analyte and clinical presentation were included in
additional models.
As the relationship between cystatin C and GFR differed among
clinical presentations, a cystatin C equation was derived using only
patients with native kidney disease. The model fit (r2) of this
equation was compared to a serum creatinine equation derived with
the same data, the MDRD equation and the Cockcroft–Gault
equation. The root mean square error between different models was
compared. Statistical significance for the difference in r2 between
equations was determined using the method of Meng et al.15 An
additional cystatin C equation was developed for transplant
recipients.
To assess performance on independent data sets, new equations
were internally validated with bootstrapping.29 Each equation was
evaluated using 500 random bootstrap samples from the full set of
data used to derive the equation. Stepwise selection was used to add
the serum analyte, age and gender to each model. Model optimism
(including stepwise selection) was determined from the mean
difference between the r2 of each bootstrapped sample and the r2
when applying that bootstrapped sample’s parameters to the original
data set. r2 adjusted for optimism was determined from the original
data r2 minus model optimism. Statistics were performed with JMP
5.1 and with SAS 8.2 (SAS Institute, Cary, NC, USA).
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